RayKnowChina Research Map
Shortlist0

HangzhouZhejiang University School of Medicine

Sir Run Run Shaw Hospital

浙江大学医学院附属邵逸夫医院

Listed for 20 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Sir Run Run Shaw Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌4 papers led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌1 paper led
  3. Hepatocellular carcinoma肝细胞癌83 papers led3 open trials led
  4. Stomach cancer胃癌44 papers led
  5. Osteosarcoma骨肉瘤10 papers led
  6. Gastrointestinal stromal tumour胃肠道间质瘤2 papers led
  7. Multiple myeloma多发性骨髓瘤4 papers led
  8. Thrombotic thrombocytopenic purpura血栓性血小板减少性紫癜1 paper led
  9. IgG4-related diseaseIgG4相关性疾病3 papers led
  10. Myasthenia gravis重症肌无力0 papers led
  11. Takayasu arteritis大动脉炎1 paper led
  12. Idiopathic pulmonary fibrosis特发性肺纤维化0 papers led
  13. Lymphangioleiomyomatosis肺淋巴管平滑肌瘤病1 paper led
  14. Amyotrophic lateral sclerosis肌萎缩侧索硬化症0 papers led
  15. Pompe disease庞贝病0 papers led
  16. Behçet disease白塞病1 paper led
  17. IgA nephropathyIgA 肾病3 papers led
  18. Niemann–Pick disease type C尼曼-匹克病 C 型0 papers led
  19. Primary biliary cholangitis原发性胆汁性胆管炎1 paper led
  20. Primary sclerosing cholangitis原发性硬化性胆管炎0 papers led

Not listed for: Hepatoblastoma, Retinoblastoma, Chordoma, Neuroblastoma, Ewing sarcoma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Fanconi anaemia, Neuromyelitis optica spectrum disorder, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Hepatic echinococcosis, Spinal muscular atrophy, Fabry disease, Duchenne muscular dystrophy, Alport syndrome, Gaucher disease, Osteogenesis imperfecta, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 4 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 0020222023: 1120232024: 1120242025: 002025

8 hospitals in Hangzhou for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma

No open trial on nasopharyngeal carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
Departments in papersENT / head & neck surgery
Papers it led4
  1. A Preliminary Study on Transcriptional Regulation of SNP Site C-1888T in the Promoter Region of Human PLUNC Gene and Nasopharyngeal Carcinoma Susceptibility.2024Genetics researchFree full text
  2. RASSF1A promotes radiosensitivity in nasopharyngeal carcinoma by promoting FoxO3a and inhibiting the Nrf2/TXNRD1 signaling pathway.2023Neoplasma
  3. LINC01433 targets miR-506-3p to promote the biological progress of nasopharyngeal carcinoma cells.2021European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  4. Functional Study of Polymorphism 1888 C>T in the Promoter Region of Human PLUNC Gene.2021The American journal of the medical sciences
All its trials on ClinicalTrials.gov, any status1
  1. Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid TumorsCompletedNCT04215978Study sitePhase 1Start 2020-01
More papers found outside PubMed (not counted)1
  1. Clinical observation of endoscopic skull base reconstruction with an anterolateral thigh free fascia flap2023Laparoscopic Endoscopic and Robotic Surgeryarticle

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 1 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.03%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

6 hospitals in Hangzhou for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma

No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesNeoadjuvant & combined treatmentRadiotherapyEarly detection & endoscopy
Departments in papersGastroenterology / hepatology
Papers it led1
  1. A retrospective cohort study to observe the efficacy and safety of Endoscopic Submucosal Dissection (ESD) with adjuvant radiotherapy for T1a-MM/T1b-SM Esophageal Squamous Cell Carcinoma (ESCC).2024PloS oneFree full text
All its trials on ClinicalTrials.gov, any status5
  1. Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).TerminatedNCT04949256Study sitePhase 3Start 2021-07
  2. Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)CompletedNCT04210115Study sitePhase 3Start 2020-02
  3. A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell CarcinomaCompletedNCT03957590Study sitePhase 3Start 2019-06
  4. A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell CarcinomaCompletedNCT03783442Study sitePhase 3Start 2018-12
  5. Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell CarcinomaStatus unknownNCT02611700Study sitePhase 3Start 2015-11
More papers found outside PubMed (not counted)8
  1. 1570P A phase I clinical trial of 5T4-antibody NK cell conjugation (IBR854 Injection) in patients with advanced solid tumor2025Annals of Oncologyarticle
  2. Safety and efficacy of sintilimab-based neoadjuvant immunochemotherapy for resectable esophageal squamous cell carcinoma: A pooled analysis2024Research Squarepreprint
  3. The roles of G protein-coupled receptor genes and the tumor microenvironment in esophageal squamous cell carcinoma2024ONCOLOGIEarticle
  4. Additional file 1 of Toosendanin targeting eEF2 impedes Topoisomerase I & II protein translation to suppress esophageal squamous cell carcinoma growth2023Figsharedataset
  5. Additional file 2 of Toosendanin targeting eEF2 impedes Topoisomerase I & II protein translation to suppress esophageal squamous cell carcinoma growth2023Figsharedataset
  6. Genetic alteration and ctDNA mutation profiling of esophageal cancer in Chinese patients.2023Journal of Clinical Oncologyconference-abstract
  7. 1373MO JUPITER-06: A randomized, double-blind, phase III study of toripalimab versus placebo in combination with first-line chemotherapy for treatment naive advanced or metastatic esophageal squamous cell carcinoma (ESCC)2021Annals of Oncologyarticle
  8. Efficacy and safety of KN046 plus paclitaxel/cisplatin as first-line treatment for unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).2021Journal of Clinical Oncologyconference-abstract

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 83 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.6%.

Papers led
83
2021–2025
Trials led
5
any status, ClinicalTrials.gov
Open trials led
3
recruiting or about to
Open trials as a site
8
led by another institution
Papers led per year
2021: 181820212022: 171720222023: 161620232024: 111120242025: 20202025

7 hospitals in Hangzhou for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 11

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Study on the Therapeutic Effect of Different Infusion Times of Tislelizumab on Postoperative High-risk Hepatocellular Carcinoma
    Phase
    N/A
    Started
    2025-12
    Registry
    NCT07243691

    Age 18 years to Not stated (registered criteria)

    Led by Sir Run Run Shaw HospitalHangzhou

  2. Recruiting
    A Clinical Study on the Safety, Tolerability and Efficacy of Neoantigen-based Personalized mRNA Therapy iNeo-Vac-R01 Plus PD-1 Inhibitor in Adjuvant Treatment of Liver Cancer Post Radical Resection
    Phase
    Phase 1/Phase 2
    Started
    2025-09
    Registry
    NCT07495215

    Age 18 years to 75 years (registered criteria)

    Led by Sir Run Run Shaw HospitalHangzhou

  3. Recruiting
    The Treatment of Bioartificial Liver With hiHep Cells After Extensive Hepatectomy
    Phase
    Early phase 1
    Started
    2021-09
    Registry
    NCT05035108

    Age 30 years to 80 years (registered criteria)

    Led by Sir Run Run Shaw HospitalHangzhou

  4. Recruiting
    Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
    Phase
    Phase 1
    Started
    2025-11
    Registry
    NCT07176650

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Bengbu, Changchun, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xi'an, Zhengzhou

  5. Recruiting
    NWRD06 DNA Plasmid for HCC After Curative Resection.
    Phase
    Phase 2
    Started
    2025-12
    Registry
    NCT07324304

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Hangzhou, Harbin

  6. Recruiting
    Phase 2 Study of WGI-0301 for Advanced HCC
    Phase
    Phase 2
    Started
    2024-07
    Registry
    NCT06309485

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesChangsha, Chengdu, Hangzhou, Harbin, Nanchang, Wuhan

  7. Recruiting
    Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
    Phase
    Phase 3
    Started
    2023-05
    Registry
    NCT05862337

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 43 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Lanzhou, Luzhou, Nanchang, Nanchong, Nanning, Nantong, Ningbo, Shanghai, Shenyang, Taizhou, Tianjin, Urumqi, Wenzhou, Xi'an, Zhengzhou

  8. Recruiting
    CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection
    Phase
    Phase 1
    Started
    2023-10
    Registry
    NCT06560827

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Shanghai, Shenyang, Tianjin, Wuhan, Zhengzhou

  9. Recruiting
    Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC
    Phase
    Phase 1/Phase 2
    Started
    2022-12
    Registry
    NCT05652920

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Hangzhou, Shanghai

  10. Recruiting
    Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2021-11
    Registry
    NCT05024214

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesBeijing, Bengbu, Changchun, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Shanghai, Shenyang, Tianjin, Zhengzhou, Zhuhai

  11. Not yet recruiting
    29-Gene Liver Cancer Subtype and Immunotherapy Effectiveness
    Phase
    Not given
    Started
    2025-08
    Registry
    NCT07100236

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Hangzhou, Hefei, Shanghai, Wenzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrence & prognosisImaging, AI & early detectionImmunotherapy & targeted drugs
Departments in papersSurgery (general/hepatobiliary/pancreatic)Medical oncologyRadiology / nuclear medicineGastroenterology / hepatology
Papers it led83
  1. G9a epigenetically suppresses CXCL10 expression and inhibits anti-tumor immunity in hepatocellular carcinoma.2026International journal of cancer
  2. Porous Silicon Particle-Assisted Mass Spectrometry Technology Unlocks Serum Metabolic Fingerprints in the Progression From Chronic Hepatitis B to Hepatocellular Carcinoma.2025ACS applied materials & interfaces
  3. Synergistic Anticancer Strategy Targeting ECM Stiffness: Integration of Matrix Softening and Mechanical Signal Transduction Blockade in Primary Liver Cancers.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  4. Lactate Metabolic Reprogramming Mediated by CircRNA-LDHA Complex Facilitates Innate Immune Evasion of Liver Cancer.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  5. APOE deficiency triggers anti-tumour activity of macrophages in liver cancer.2025Cancer gene therapy
  6. Phase separation of EEF1E1 promotes tumor stemness via PTEN/AKT-mediated DNA repair in hepatocellular carcinoma.2025Cancer letters
  7. Cone-beam CT radiomics for early response assessment in liver stereotactic body radiation therapy: Results of a pilot study.2025Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique
  8. The heterogeneity of cellular metabolism in the tumour microenvironment of hepatocellular carcinoma with portal vein tumour thrombus.2025Cell proliferationFree full text
  9. Sorafenib Promotes Treg Cell Differentiation To Compromise Its Efficacy via VEGFR/AKT/Foxo1 Signaling in Hepatocellular Carcinoma.2025Cellular and molecular gastroenterology and hepatologyFree full text
  10. Deciphering the methylation landscape of long noncoding RNAs in hepatocellular carcinoma: a focus on LINC00942.2025Clinical epigeneticsFree full text
  11. CDK4 as a Prognostic Marker of Hepatocellular Carcinoma and CDK4 Inhibitors as Potential Therapeutics.2025Current medicinal chemistryFree full text
  12. Serum magnesium predictive value in hepatocellular carcinoma patients on first-line immunotherapy: a retrospective study.2025Frontiers in immunologyFree full text
  13. The glucose sensor NSUN2-m5C modification regulates tumor-immune glucose metabolism reprogramming to drive hepatocellular carcinoma evolution.2025International journal of biological sciencesFree full text
  14. Central venous pressure-guided fluid management in hepatectomy under remimazolam: Impact on postoperative renal and gastrointestinal recovery.2025Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  15. Liver-specific gene PGRMC1 blocks c-Myc-induced hepatocarcinogenesis through ER stress-independent PERK activation.2025Nature communicationsFree full text
  16. Noninvasive prognostic classification of ITH in HCC with multi-omics insights and therapeutic implications.2025Science advancesFree full text
  17. LZTS2 methylation as a potential diagnostic and prognostic marker in LIHC and STAD: Evidence from bioinformatics and in vitro analyses.2025Scientific reportsFree full text
  18. Targeted Intracellular Copper Reservoir Enhances Liver Cancer Immunotherapy.2025Small (Weinheim an der Bergstrasse, Germany)Free full text
  19. Minimally invasive versus open liver resection for hepatocellular carcinoma with microvascular invasion: a propensity score-matching study.2025Surgical endoscopy
  20. Establishment of MS LOC platform and its pilot application in clinical lipidomics.2025Talanta
  21. Apatinib regulates the glycolysis of vascular endothelial cells through PI3K/AKT/PFKFB3 pathway in hepatocellular carcinoma.2025World journal of gastroenterologyFree full text
  22. S100A6 drives lymphatic metastasis of liver cancer via activation of the RAGE/NF-kB/VEGF-D pathway.2024Cancer letters
  23. MicroRNA let-7c-5p Alleviates in Hepatocellular Carcinoma by Targeting Enhancer of Zeste Homolog 2: A Study Intersecting Bioinformatic Analysis and Validated Experiments.2024Critical reviews in immunology
  24. A disulfidptosis-related lncRNA signature for analyzing tumor microenvironment and clinical prognosis in hepatocellular carcinoma.2024Frontiers in immunologyFree full text
  25. Activation of IGFBP4 via unconventional mechanism of miRNA attenuates metastasis of intrahepatic cholangiocarcinoma.2024Hepatology internationalFree full text
  26. CCT3/ACTN4/TFRC axis protects hepatocellular carcinoma cells from ferroptosis by inhibiting iron endocytosis.2024Journal of experimental & clinical cancer research : CRFree full text
  27. Concomitant Medications Alter Clinical Outcomes in Patients with Advanced Digestive Tract Cancer Receiving PD-1 Checkpoint Inhibitors Combined with Antiangiogenetic Agents.2024Journal of gastrointestinal cancer
  28. Editorial for "Magnetic Resonance Deep Learning Radiomic Model Based on Distinct Metastatic Vascular Patterns for Evaluating Recurrence-Free Survival in Hepatocellular Carcinoma".2024Journal of magnetic resonance imaging : JMRI
  29. Reply to the letter 'Preoperative MRI in predicting tumour recurrence of hepatocellular carcinoma: Does AI have a role?'.2024Liver international : official journal of the International Association for the Study of the Liver
  30. Multitask deep learning for prediction of microvascular invasion and recurrence-free survival in hepatocellular carcinoma based on MRI images.2024Liver international : official journal of the International Association for the Study of the Liver
  31. Signaling pathways in liver cancer: pathogenesis and targeted therapy.2024Molecular biomedicineFree full text
  32. Machine Learning Diagnostic Model for Hepatocellular Carcinoma Based on Liquid-Liquid Phase Separation and Ferroptosis-Related Genes.2024The Turkish journal of gastroenterology : the official journal of Turkish Society of GastroenterologyFree full text
  33. Prognostic significance of CTNNB1 mutation in hepatocellular carcinoma: a systematic review and meta-analysis.2023AgingFree full text
  34. Robot Assisted Laparoscopy Combined with Thoracoscopy in the Treatment of Hepatocellular Carcinoma with Inferior Vena Cava Tumor Thrombus.2023Annals of surgical oncology
  35. Small-molecule High-throughput Screening Identifies an MEK Inhibitor PD198306 that Enhances Sorafenib Efficacy via MCL-1 and BIM in Hepatocellular Carcinoma Cells.2023Combinatorial chemistry & high throughput screeningFree full text
  36. Aberrant DNA Methylation Patterns of Deleted in Liver Cancer 1 Isoforms in Hepatocellular Carcinoma.2023DNA and cell biology
  37. A novel multimodal deep learning model for preoperative prediction of microvascular invasion and outcome in hepatocellular carcinoma.2023European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  38. Identification and development of a novel risk model based on cuproptosis-associated RNA methylation regulators for predicting prognosis and characterizing immune status in hepatocellular carcinoma.2023Hepatology international
  39. Evaluation of PD-L1 as a biomarker for immunotherapy for hepatocellular carcinoma: systematic review and meta-analysis.2023Immunotherapy
  40. cDCBLD2 mediates sorafenib resistance in hepatocellular carcinoma by sponging miR-345-5p binding to the TOP2A coding sequence.2023International journal of biological sciencesFree full text
  41. Golgi-protein 73 facilitates vimentin polymerization in hepatocellular carcinoma.2023International journal of biological sciencesFree full text
  42. Bulk and single-cell transcriptome profiling reveal extracellular matrix mechanical regulation of lipid metabolism reprograming through YAP/TEAD4/ACADL axis in hepatocellular carcinoma.2023International journal of biological sciencesFree full text
  43. Important oncogenic and immunogenic roles of SPP1 and CSF1 in hepatocellular carcinoma.2023Medical oncology (Northwood, London, England)Free full text
  44. Development and validation of a clinical-radiomics model to predict recurrence for patients with hepatocellular carcinoma after curative resection.2023Medical physics
  45. An aging-related gene signature to predict the prognosis of hepatocellular carcinoma.2023MedicineFree full text
  46. Cytoskeleton remodeling mediated by circRNA-YBX1 phase separation suppresses the metastasis of liver cancer.2023Proceedings of the National Academy of Sciences of the United States of AmericaFree full text
  47. The difficulty grade of laparoscopic hepatectomy for hepatocellular carcinoma correlates with long-term outcomes.2023Updates in surgeryFree full text
  48. Safety and feasibility of laparoscopic liver resection for intrahepatic cholangiocarcinoma: a propensity score-matched study.2023World journal of surgical oncologyFree full text
  49. Radiomics Analysis of Gd-EOB-DTPA Enhanced Hepatic MRI for Assessment of Functional Liver Reserve.2022Academic radiology
  50. ASO Author Reflections: Reflections on the Treatment Strategy of Hepatocellular Carcinoma with Inferior Vena Cava Thrombus in the New Era.2022Annals of surgical oncology
  51. Laparoscopic Orthotopic Right Hemihepatectomy by Anterior Approach Combined with Inferior Vena Cava Thrombectomy.2022Annals of surgical oncology
  52. Complete response after combined chemoembolization and Huaier therapy for pulmonary metastasis of hepatocellular carcinoma: A case report.2022Asian journal of surgery
  53. Efficacy and safety of PD-1 inhibitor combined with antiangiogenic therapy for unresectable hepatocellular carcinoma: A multicenter retrospective study.2022Cancer medicineFree full text
  54. Co-targeting WIP1 and PARP induces synthetic lethality in hepatocellular carcinoma.2022Cell communication and signaling : CCSFree full text
  55. B3galt5 deficiency attenuates hepatocellular carcinoma by suppressing mTOR/p70s6k-mediated glycolysis.2022Cellular and molecular life sciences : CMLSFree full text
  56. Screening of Prognostic Markers for Hepatocellular Carcinoma Patients Based on Multichip Combined Analysis.2022Computational and mathematical methods in medicineFree full text
  57. Construction of a Novel Oxidative Stress Response-Related Gene Signature for Predicting the Prognosis and Therapeutic Responses in Hepatocellular Carcinoma.2022Disease markersFree full text
  58. Comprehensive analysis of cuproptosis-related lncRNAs for prognostic significance and immune microenvironment characterization in hepatocellular carcinoma.2022Frontiers in immunologyFree full text
  59. Hepatic epithelioid angiomyolipoma mimicking hepatocellular carcinoma on MR and 18F-FDG PET/CT imaging: A case report and literature review.2022Hellenic journal of nuclear medicine
  60. Multi-Omics and Artificial Intelligence-Guided Data Integration in Chronic Liver Disease: Prospects and Challenges for Precision Medicine.2022Omics : a journal of integrative biology
  61. The Invasive Potential of Hepatoma Cells Induced by Radiotherapy is Related to the Activation of Hepatic Stellate Cells and Could be Inhibited by EGCG Through the TLR4 Signaling Pathway.2022Radiation research
  62. CRISPR-Cas9-based genome-wide screening identified novel targets for treating sorafenib-resistant hepatocellular carcinoma: a cross-talk between FGF21 and the NRF2 pathway.2022Science China. Life sciences
  63. Efficacy of laparoscopic repeat hepatectomy compared with open repeat hepatectomy: a single-center, propensity score matching study.2022World journal of surgical oncologyFree full text
  64. A pyroptosis-related gene signature predicts prognosis and immune microenvironment in hepatocellular carcinoma.2022World journal of surgical oncologyFree full text
  65. The impact of body mass index on short-term and long-term surgical outcomes of laparoscopic hepatectomy in liver carcinoma patients: a retrospective study.2022World journal of surgical oncologyFree full text
  66. Aptamer and Peptide-Modified Lipid-Based Drug Delivery Systems in Application of Combined Sequential Therapy of Hepatocellular Carcinoma.2021ACS biomaterials science & engineering
  67. ZnS@BSA Nanoclusters Potentiate Efficacy of Cancer Immunotherapy.2021Advanced materials (Deerfield Beach, Fla.)
  68. An integrated electrochemical POCT platform for ultrasensitive circRNA detection towards hepatocellular carcinoma diagnosis.2021Biosensors & bioelectronics
  69. Sirt1 deacetylates and stabilizes p62 to promote hepato-carcinogenesis.2021Cell death & diseaseFree full text
  70. TAK1 Is a Novel Target in Hepatocellular Carcinoma and Contributes to Sorafenib Resistance.2021Cellular and molecular gastroenterology and hepatologyFree full text
  71. Diagnostic efficacy of contrast-enhanced ultrasound versus MRI Liver Imaging Reporting and Data System (LI-RADS) for categorising hepatic observations in patients at risk of hepatocellular carcinoma.2021Clinical radiology
  72. Case Report: Clinical Responses to Tislelizumab as a First-Line Therapy for Primary Hepatocellular Carcinoma With B-Cell Indolent Lymphoma.2021Frontiers in immunologyFree full text
  73. Letter to the Editor: Predicting Survival After Hepatocellular Carcinoma Resection Using Deep-Learning on Histological Slides.2021Hepatology (Baltimore, Md.)
  74. Long noncoding RNA network: Novel insight into hepatocellular carcinoma metastasis (Review).2021International journal of molecular medicineFree full text
  75. Adjuvant transarterial chemoembolization to sorafenib in unresectable hepatocellular carcinoma: A meta-analysis.2021Journal of gastroenterology and hepatology
  76. Laparoscopic Portal Territory Hepatectomy (Extended Segment 5) by an Indocyanine Green Fluorescent Dual Staining Technique (Video).2021Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  77. Circular RNAs: characteristics, biogenesis, mechanisms and functions in liver cancer.2021Journal of hematology & oncologyFree full text
  78. The Preoperative Prognostic Nutritional Index in Hepatocellular Carcinoma After Curative Hepatectomy: A Retrospective Cohort Study and Meta-Analysis.2021Journal of investigative surgery : the official journal of the Academy of Surgical Research
  79. Current status of laparoscopic hepatectomy for the treatment of hepatocellular carcinoma: A systematic literature review.2021MedicineFree full text
  80. A tumor-suppressive circular RNA mediates uncanonical integrin degradation by the proteasome in liver cancer.2021Science advancesFree full text
  81. UBQLN1 mediates sorafenib resistance through regulating mitochondrial biogenesis and ROS homeostasis by targeting PGC1β in hepatocellular carcinoma.2021Signal transduction and targeted therapyFree full text
  82. Safety and feasibility of laparoscopic liver resection for hepatocellular carcinoma with clinically significant portal hypertension: a propensity score-matched study.2021Surgical endoscopy
  83. A Ring in the Liver.2021The American journal of gastroenterology
Chinese-language papers (not in the count)4
  1. [Clinical study on early predictors of concurrent bile duct injury following TACE in patients with liver cancer].2023Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  2. [Progress in surgical treatment of hepatocellular carcinoma with tumor thrombus in the inferior vena cava].2023Zhonghua wai ke za zhi [Chinese journal of surgery]
  3. [Ten-year retrospect of ALPPS in the treatment of hepatocellular carcinoma:an eternal concept with cautious technologic choice].2022Zhonghua wai ke za zhi [Chinese journal of surgery]
  4. [The clinical value of terminal branches portal vein embolization for hepatocellular carcinoma with insufficient future liver remnant].2021Zhonghua wai ke za zhi [Chinese journal of surgery]
All its trials on ClinicalTrials.gov, any status26
  1. Study on the Therapeutic Effect of Different Infusion Times of Tislelizumab on Postoperative High-risk Hepatocellular CarcinomaRecruitingNCT07243691Lead sponsorN/AStart 2025-12
  2. The Treatment of Bioartificial Liver With hiHep Cells After Extensive HepatectomyRecruitingNCT05035108Lead sponsorEarly phase 1Start 2021-09
  3. Laparoscopic Versus Open Liver Resection in the Treatment of Hepatocellular CarcinomaStatus unknownNCT01768741Lead sponsorN/AStart 2012-12
  4. A Clinical Study on the Safety, Tolerability and Efficacy of Neoantigen-based Personalized mRNA Therapy iNeo-Vac-R01 Plus PD-1 Inhibitor in Adjuvant Treatment of Liver Cancer Post Radical ResectionRecruitingNCT07495215Lead (inferred)Phase 1/Phase 2Start 2025-09
  5. Parenteral Fish Oil in Major Laparoscopic Abdominal SurgeryStatus unknownNCT01819961Lead (inferred)Phase 4Start 2013-04
  6. NWRD06 DNA Plasmid for HCC After Curative Resection.RecruitingNCT07324304Study sitePhase 2Start 2025-12
  7. 29-Gene Liver Cancer Subtype and Immunotherapy EffectivenessNot yet recruitingNCT07100236Study siteStart 2025-08
  8. Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular CarcinomaRecruitingNCT07176650Study sitePhase 1Start 2025-11
  9. Phase 2 Study of WGI-0301 for Advanced HCCRecruitingNCT06309485Study sitePhase 2Start 2024-07
  10. Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.RecruitingNCT05862337Study sitePhase 3Start 2023-05
  11. CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical ResectionRecruitingNCT06560827Study sitePhase 1Start 2023-10
  12. Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCCRecruitingNCT05652920Study sitePhase 1/Phase 2Start 2022-12
  13. Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid TumorsRecruitingNCT05024214Study sitePhase 1/Phase 2Start 2021-11
  14. A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCCWithdrawnNCT05212922Study sitePhase 2Start 2023-06
  15. PM8002 in Combination With Chemotherapy as First Line Therapy in Hepatocellular CarcinomaCompletedNCT05864105Study sitePhase 2Start 2022-04
  16. Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)TerminatedNCT04246177Study sitePhase 3Start 2020-05
  17. A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCCCompletedNCT03764293Study sitePhase 3Start 2019-06
  18. A Phase I/II Study of AST-3424 in Subjects With Advanced Solid TumorsActive, not recruitingNCT06239155Study sitePhase 1/Phase 2Start 2019-09
  19. A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction CancerCompletedNCT03941873Study sitePhase 1/Phase 2Start 2019-02
  20. Study of EOC317 in Chinese Patients With Advanced Solid TumorsStatus unknownNCT03583125Study sitePhase 1Start 2018-05
  21. Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)CompletedNCT03713593Study sitePhase 3Start 2018-12
  22. Study of BGB-A317 in Participants With Previously Treated Unresectable HCCCompletedNCT03419897Study sitePhase 2Start 2018-04
  23. A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular CarcinomaCompletedNCT03434379Study sitePhase 3Start 2018-03
  24. A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)CompletedNCT03412773Study sitePhase 3Start 2017-12
  25. Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular CarcinomaCompletedNCT01988493Study sitePhase 1/Phase 2Start 2014-01
  26. Axitinib For The Treatment Of Advanced Hepatocellular CarcinomaCompletedNCT01210495Study sitePhase 2Start 2010-12

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 44 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.4%.

Papers led
44
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
11
led by another institution
Papers led per year
2021: 111120212022: 121220222023: 7720232024: 4420242025: 992025

9 hospitals in Hangzhou for stomach cancer218 hospitals in China for stomach cancer

Open trials with this hospital 11

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
    Phase
    Phase 3
    Started
    2026-04
    Registry
    NCT07385703

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 62 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengde, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanchong, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yangzhou, Zhengzhou

  2. Recruiting
    Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy
    Phase
    Phase 3
    Started
    2026-12
    Registry
    NCT07789184

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 25 listed hospitals as study sitesBeijing, Changchun, Chongqing, Dalian, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Tianjin, Urumqi, Wuhan, Xi'an

  3. Recruiting
    Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
    Phase
    Phase 3
    Started
    2025-02
    Registry
    NCT06731478

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changzhou, Fuzhou, Hangzhou, Harbin, Hefei, Jinan, Lanzhou, Linyi, Shanghai, Shenyang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yinchuan, Zhengzhou

  4. Recruiting
    A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
    Phase
    Phase 2
    Started
    2025-02
    Registry
    NCT06760819

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Changsha, Hangzhou, Shanghai

  5. Recruiting
    Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
    Phase
    Not given
    Started
    2025-02
    Registry
    NCT06846996

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Guangzhou, Haikou, Hangzhou, Nanjing, Shanghai, Shantou, Shenyang, Taiyuan, Taizhou, Tianjin, Xuzhou, Zhengzhou

  6. Recruiting
    A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2025-07
    Registry
    NCT07066657

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Changsha, Chongqing, Hangzhou, Harbin, Shanghai, Wuhan, Zhengzhou

  7. Recruiting
    A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
    Phase
    Phase 1/Phase 2
    Started
    2025-08
    Registry
    NCT07070232

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesChongqing, Hangzhou, Tianjin, Wuhan

  8. Recruiting
    Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
    Phase
    Phase 1/Phase 2
    Started
    2024-06
    Registry
    NCT06324357

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesChangchun, Hangzhou, Harbin, Nanjing, Shanghai, Tianjin, Zhengzhou

  9. Recruiting
    Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
    Phase
    Phase 1/Phase 2
    Started
    2024-09
    Registry
    NCT06469944

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesBeijing, Fuzhou, Hangzhou, Nanchang, Shanghai, Urumqi, Xiamen, Zhengzhou

  10. Recruiting
    A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
    Phase
    Phase 3
    Started
    2024-11
    Registry
    NCT06532006

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 34 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Lanzhou, Nanchang, Nanjing, Qingdao, Shanghai, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Xiamen, Xuzhou, Yinchuan, Zhengzhou

  11. Recruiting
    Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
    Phase
    Phase 1
    Started
    2021-06
    Registry
    NCT04900818

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Harbin, Hefei, Shanghai, Shenyang, Tianjin, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesSurgeryImaging & AIPeritoneal spread & advanced disease
Departments in papersSurgery (general/hepatobiliary/pancreatic)Medical oncologyGastroenterology / hepatologyPathology / laboratory medicine
Papers it led44
  1. Prior immunotherapy enhances survival outcomes of third-line apatinib treatment in advanced gastric cancer: A retrospective cohort study.2026International journal of cancer
  2. Response to anaplastic lymphoma kinase inhibitor in gastric cancer harboring DCTN1-ALK fusion: a case report and review.2025Frontiers in immunologyFree full text
  3. Case Report: Synchronous pancreatic sarcomatoid carcinoma and gastric cancer: a case study with literature review.2025Frontiers in immunologyFree full text
  4. Case report: Chemotherapy plus sintilimab for the treatment of gastroesophageal junction hepatoid adenocarcinoma with liver metastasis: a case study with literature review.2025Frontiers in immunologyFree full text
  5. CLEVER-1 blockade reprograms TAMs to overcome anti-PD-1 resistance in gastric cancer.2025Journal for immunotherapy of cancerFree full text
  6. Early Oral Feeding is Safe and Comfortable in Patients with Gastric Cancer Undergoing Radical Total Gastrectomy.2025Nutrition and cancerRCT
  7. Application of Problem-Oriented Nursing Model Combined with Early Enteral Nutrition Support in the Perioperative Period of Stage II/III Gastric Cancer Patients.2025Nutrition and cancerRCT
  8. Global, regional, and national burdens of five main digestive system cancers in adolescents and young adults from 1990 to 2021 based on the Global Burden of Disease Study 2021: A cross-sectional study.2025PloS oneFree full text
  9. Design, optimization, and ADMET evaluation of S11a-0000168202: A promising LIMK1 inhibitor for gastric cancer treatment.2025PloS oneFree full text
  10. LZTS2 methylation as a potential diagnostic and prognostic marker in LIHC and STAD: Evidence from bioinformatics and in vitro analyses.2025Scientific reportsFree full text
  11. Reduced expression of E-cadherin correlates with poor prognosis and unfavorable clinicopathological features in gastric carcinoma: a meta-analysis.2024AgingFree full text
  12. Concomitant Medications Alter Clinical Outcomes in Patients with Advanced Digestive Tract Cancer Receiving PD-1 Checkpoint Inhibitors Combined with Antiangiogenetic Agents.2024Journal of gastrointestinal cancer
  13. Acute therapy-related myelodysplastic syndromes following capecitabine and oxaliplatin therapy in gastric malignant tumor: A case report.2024MedicineFree full text
  14. Multi-omics features of immunogenic cell death in gastric cancer identified by combining single-cell sequencing analysis and machine learning.2024Scientific reportsFree full text
  15. Preoperative and postoperative clinical signatures of postgastrectomy venous thromboembolism in patients with gastric cancer: A retrospective cohort study.2023Asian journal of surgery
  16. AKR1B10 regulates M2 macrophage polarization to promote the malignant phenotype of gastric cancer.2023Bioscience reportsFree full text
  17. SHP2 inhibition mitigates adaptive resistance to MEK inhibitors in KRAS-mutant gastric cancer through the suppression of KSR1 activity.2023Cancer letters
  18. Rab31 promotes metastasis and cisplatin resistance in stomach adenocarcinoma through Twist1-mediated EMT.2023Cell death & diseaseFree full text
  19. RNautophagic regulation of DNMT3a-dependent DNA methylation by Linc00942 enhances chemoresistance in gastric cancer.2023Clinical and translational medicineFree full text
  20. The Learning Curve Study of Robotic Distal Gastrectomy: an Analysis of Outcomes of the First 67 Consecutive Cases at a High-Volume Gastric Center.2023Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  21. CONUT can be a predictor of postoperative complications after laparoscopic-assisted radical gastrectomy for elderly gastric cancer patients.2023MedicineFree full text
  22. MiR-1-3p targets CENPF to repress tumor-relevant functions of gastric cancer cells.2022BMC gastroenterologyFree full text
  23. Anti-PD-1 combined with targeted therapy: Theory and practice in gastric and colorectal cancer.2022Biochimica et biophysica acta. Reviews on cancer
  24. Application of Overlap Gastroduodenostomy in Billroth I Anastomosis after Totally Laparoscopic Distal Gastrectomy for Gastric Cancer.2022Canadian journal of gastroenterology & hepatologyFree full text
  25. Immune microenvironment characteristics and their implications for immune checkpoint inhibitor efficacy in HER2-overexpressing gastric cancer.2022Clinical and experimental immunology
  26. LncRNA LINC00942 promotes chemoresistance in gastric cancer by suppressing MSI2 degradation to enhance c-Myc mRNA stability.2022Clinical and translational medicineFree full text
  27. Single-cell sequencing analysis reveals gastric cancer microenvironment cells respond vastly different to oxidative stress.2022Journal of translational medicineFree full text
  28. Case report: apatinib plus selexipag as a novel therapy for pulmonary tumor thrombotic microangiopathy accompanied by pulmonary hypertension associated with gastric carcinoma.2022MedicineFree full text
  29. Clinical significance and prospective molecular mechanism of NUF2 in gastric cancer exploration: A comprehensive study based on the GeneChip, GEO, Oncomine, and TCGA databases.2022MedicineFree full text
  30. HOXC10 indicates poor survival outcome in gastric cancer and promotes G1/S cell cycle transition through transcriptional repression of p21.2022Neoplasma
  31. The keratin 17/YAP/IL6 axis contributes to E-cadherin loss and aggressiveness of diffuse gastric cancer.2022Oncogene
  32. The value of CT-based radiomics nomogram in differential diagnosis of different histological types of gastric cancer.2022Physical and engineering sciences in medicineFree full text
  33. Cadherin 11-mediated juxtacrine interaction of gastric cancer cells and fibroblasts promotes metastasis via YAP/tenascin-C signaling.2022Science bulletin
  34. Creatinine-to-cystatin C ratio as a marker of skeletal muscle mass for predicting postoperative complications in patients undergoing gastric cancer surgery.2021Annals of palliative medicine
  35. A genomic-clinicopathologic Nomogram for the preoperative prediction of lymph node metastasis in gastric cancer.2021BMC cancerFree full text
  36. Value of CT Imaging in the Differentiation of Gastric Leiomyoma From Gastric Stromal Tumor.2021Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes
  37. Simultaneous Recognition of Atrophic Gastritis and Intestinal Metaplasia on White Light Endoscopic Images Based on Convolutional Neural Networks: A Multicenter Study.2021Clinical and translational gastroenterologyFree full text
  38. CK1δ stimulates ubiquitination-dependent proteasomal degradation of ATF4 to promote chemoresistance in gastric Cancer.2021Clinical and translational medicineFree full text
  39. Comparison of laparoscopic proximal gastrectomy with double-tract reconstruction and laparoscopic total gastrectomy for proximal gastric cancer with stage cT1-2.2021MedicineFree full text
  40. RORβ suppresses the stemness of gastric cancer cells by downregulating the activity of the Wnt signaling pathway.2021Oncology reportsFree full text
  41. High GP73 Expression Correlates with Poor Response to Neoadjuvant Chemotherapy and Survival in Gastric Cancer: A Tissue Microarray Study.2021Pathology oncology research : PORFree full text
  42. Generalized methodology for radiomic feature selection and modeling in predicting clinical outcomes.2021Physics in medicine and biology
  43. Quinone oxidoreductase 1 is overexpressed in gastric cancer and associated with outcome of adjuvant chemotherapy and survival.2021World journal of gastroenterologyFree full text
  44. Preoperative Controlling Nutritional Status (CONUT) score predicts short-term outcomes of patients with gastric cancer after laparoscopy-assisted radical gastrectomy.2021World journal of surgical oncologyFree full text
Chinese-language papers (not in the count)1
  1. [Clinical and pathological characteristics of gastric adenocarcinoma of fundic gland type].2023Zhonghua yi xue za zhi
All its trials on ClinicalTrials.gov, any status41
  1. Clinical Trial to Evaluate the Efficacy and Safety of a Thoracic and Abdominal Endoscopic Surgical SystemStatus unknownNCT06587152Lead (inferred)N/AStart 2024-01
  2. Parenteral Fish Oil in Major Laparoscopic Abdominal SurgeryStatus unknownNCT01819961Lead (inferred)Phase 4Start 2013-04
  3. Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion TherapyRecruitingNCT07789184Study sitePhase 3Start 2026-12
  4. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT07385703Study sitePhase 3Start 2026-04
  5. Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction CancerRecruitingNCT06731478Study sitePhase 3Start 2025-02
  6. A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)RecruitingNCT06760819Study sitePhase 2Start 2025-02
  7. A Study of MRG007 (ARR-217) in Patients With Advanced Solid TumorsRecruitingNCT07066657Study sitePhase 1Start 2025-07
  8. A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant TumorsRecruitingNCT07070232Study sitePhase 1/Phase 2Start 2025-08
  9. Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in ChinaRecruitingNCT06846996Study siteStart 2025-02
  10. A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric CancerRecruitingNCT06532006Study sitePhase 3Start 2024-11
  11. Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has SpreadRecruitingNCT06324357Study sitePhase 1/Phase 2Start 2024-06
  12. Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)RecruitingNCT06469944Study sitePhase 1/Phase 2Start 2024-09
  13. Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid TumorsRecruitingNCT04900818Study sitePhase 1Start 2021-06
  14. Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)Active, not recruitingNCT06710132Study sitePhase 1/Phase 2Start 2025-01
  15. A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)Active, not recruitingNCT06356311Study sitePhase 3Start 2024-05
  16. A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.Active, not recruitingNCT06116136Study sitePhase 1/Phase 2Start 2024-08
  17. Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) OverexpressionCompletedNCT05052801Study sitePhase 3Start 2022-03
  18. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.TerminatedNCT05111626Study sitePhase 3Start 2022-03
  19. Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)Active, not recruitingNCT04704934Study sitePhase 3Start 2021-05
  20. A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal CancersActive, not recruitingNCT05152147Study sitePhase 3Start 2021-12
  21. Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR AlterationsStatus unknownNCT05019794Study sitePhase 2Start 2020-05
  22. Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China ExtensionCompletedNCT04882241Study sitePhase 3Start 2020-07
  23. Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid TumorsCompletedNCT04400383Study sitePhase 1Start 2020-06
  24. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)Active, not recruitingNCT04152499Study sitePhase 1/Phase 2Start 2020-02
  25. Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell InjectionActive, not recruitingNCT04581473Study sitePhase 1/Phase 2Start 2020-10
  26. HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric CancerStatus unknownNCT04486651Study sitePhase 3Start 2020-09
  27. A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction CancerCompletedNCT03941873Study sitePhase 1/Phase 2Start 2019-02
  28. A Study of Gentuximab + Paclitaxel in Patients With Advanced Gastric or Gastroesophageal Junction CancerCompletedNCT04053205Study sitePhase 1/Phase 2Start 2019-11
  29. Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ CancerCompletedNCT04082364Study sitePhase 2/Phase 3Start 2019-09
  30. Laparoscopic D2 Distal Gastrectomy Following Neoadjuvant Chemotherapy for Locally Advanced Gastric CancersStatus unknownNCT03468712Study siteN/AStart 2018-03
  31. A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction CancerCompletedNCT03694522Study sitePhase 2Start 2018-09
  32. Study of EOC317 in Chinese Patients With Advanced Solid TumorsStatus unknownNCT03583125Study sitePhase 1Start 2018-05
  33. Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)CompletedNCT03615326Study sitePhase 3Start 2018-10
  34. Incidence of Pancreatic Fistula After Radical GastrectomyStatus unknownNCT03391687Study siteStart 2017-12
  35. A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal CancerCompletedNCT02898077Study sitePhase 3Start 2017-03
  36. Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)CompletedNCT03221426Study sitePhase 3Start 2017-10
  37. Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)Status unknownNCT02461407Study sitePhase 2/Phase 3Start 2015-06
  38. A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction CancerCompletedNCT02178956Study sitePhase 3Start 2014-10
  39. A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric CancerCompletedNCT01774786Study sitePhase 3Start 2013-06
  40. A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric CancerTerminatedNCT01641939Study sitePhase 2/Phase 3Start 2012-09
  41. S-1 Plus Oxaliplatin Compared With Fluorouracil, Leucovorin Calcium Plus Oxaliplatin as Perioperative Chemotherapy for Advanced Gastric CarcinomaCompletedNCT01364376Study siteN/AStart 2011-06

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 10 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.4%.

Papers led
10
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 3320212022: 2220222023: 3320232024: 1120242025: 112025

22 hospitals in Hangzhou for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicinePathology / laboratory medicine

Over half of these papers are lab or animal studies.

Papers it led10
  1. Sequential Therapy for Osteosarcoma and Bone Regeneration via Chemodynamic Effect and Cuproptosis Using a 3D-Printed Scaffold with TME-Responsive Hydrogel.2025Small (Weinheim an der Bergstrasse, Germany)
  2. In vivo therapy of osteosarcoma using anion transporters-based supramolecular drugs.2024Journal of nanobiotechnology
  3. Copper-Loaded Nanoheterojunction Enables Superb Orthotopic Osteosarcoma Therapy via Oxidative Stress and Cell Cuproptosis.2023ACS nano
  4. A novel circular RNA circRBMS3 regulates proliferation and metastasis of osteosarcoma by targeting miR-424-eIF4B/YRDC axis.2023Aging
  5. 99mTc-MDP Bone Scan and 18F-FDG PET/CT Imaging of Primary Hepatic Osteosarcoma.2023Nuklearmedizin. Nuclear medicine
  6. Nomogram for predicting disease-specific survival in osteosarcoma.2022Chinese medical journal
  7. Destabilization of macrophage migration inhibitory factor by 4-IPP reduces NF-κB/P-TEFb complex-mediated c-Myb transcription to suppress osteosarcoma tumourigenesis.2022Clinical and translational medicine
  8. EIF4A3-induced circular RNA PRKAR1B promotes osteosarcoma progression by miR-361-3p-mediated induction of FZD4 expression.2021Cell death & disease
  9. TGF‑β inhibitor RepSox suppresses osteosarcoma via the JNK/Smad3 signaling pathway.2021International journal of oncology
  10. Predictive model for the 5-year survival status of osteosarcoma patients based on the SEER database and XGBoost algorithm.2021Scientific reports
Chinese-language papers (not in the count)1
  1. [CircRNA circTNPO1 promotes the proliferation and metastasis of osteosarcoma by sponging miR-338-3p].2022Zhonghua zhong liu za zhi [Chinese journal of oncology]
Earlier papers (2016–2020)13
  1. The multiple function of long noncoding RNAs in osteosarcoma progression, drug resistance and prognosis.2020Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  2. ML264 inhibits osteosarcoma growth and metastasis via inhibition of JAK2/STAT3 and WNT/β-catenin signalling pathways.2020Journal of cellular and molecular medicine
  3. CircECE1 activates energy metabolism in osteosarcoma by stabilizing c-Myc.2020Molecular cancer
  4. Lycorine Induces Apoptosis and G1 Phase Arrest Through ROS/p38 MAPK Signaling Pathway in Human Osteosarcoma Cells In Vitro and In Vivo.2020Spine
  5. Glabridin inhibits osteosarcoma migration and invasion via blocking the p38- and JNK-mediated CREB-AP1 complexes formation.2019Journal of cellular physiology
  6. CircMYO10 promotes osteosarcoma progression by regulating miR-370-3p/RUVBL1 axis to enhance the transcriptional activity of β-catenin/LEF1 complex via effects on chromatin remodeling.2019Molecular cancer
  7. Circular RNA circTADA2A promotes osteosarcoma progression and metastasis by sponging miR-203a-3p and regulating CREB3 expression.2019Molecular cancer
  8. Identification of Key Genes and miRNAs in Osteosarcoma Patients with Chemoresistance by Bioinformatics Analysis.2018BioMed research international
  9. Honokiol induces apoptosis and autophagy via the ROS/ERK1/2 signaling pathway in human osteosarcoma cells in vitro and in vivo.2018Cell death & disease
  10. Application of the alteration uptake ratio of 99mTc-MIBI scintigraphy for evaluating the efficacy of neoadjuvant chemotherapy in osteosarcoma patients.2018Hellenic journal of nuclear medicine
  11. CircFAT1 sponges miR-375 to promote the expression of Yes-associated protein 1 in osteosarcoma cells.2018Molecular cancer
  12. A miR-135b-TAZ positive feedback loop promotes epithelial-mesenchymal transition (EMT) and tumorigenesis in osteosarcoma.2017Cancer letters
  13. The TAZ-miR-224-SMAD4 axis promotes tumorigenesis in osteosarcoma.2017Cell death & disease

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 2 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.4%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 002025

16 hospitals in Hangzhou for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
    Phase
    Phase 2/Phase 3
    Started
    2026-05
    Registry
    NCT07379047

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shijiazhuang, Taiyuan, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 4 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.2%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 0020242025: 222025

9 hospitals in Hangzhou for multiple myeloma178 hospitals in China for multiple myeloma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
    Phase
    Phase 1
    Started
    2026-05
    Registry
    NCT07477587

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Weifang, Wenzhou, Wuhan, Wuxi, Xiamen, Xuzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesBispecific & antibody drugsDiagnosis, MRD & risk
Departments in papersPathology / laboratory medicine
Papers it led4
  1. Psychometric properties of the Chinese version of the M.D. Anderson symptom Inventory-Multiple Myeloma Module: a translation and validation study.2025BMC cancerFree full text
  2. Interferon Regulatory Factor 4: An Alternative Marker for Plasma Cells in Daratumumab-Treated Patients With Multiple Myeloma.2025International journal of laboratory hematology
  3. Assessment tools for patient-reported outcomes in multiple myeloma.2023Supportive care in cancer : official journal of the Multinational Association of Supportive Care in CancerFree full text
  4. Respiratory manifestation of yellow nail syndrome: a case report and literature review.2021The Journal of international medical researchFree full text
All its trials on ClinicalTrials.gov, any status6
  1. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple MyelomaRecruitingNCT07477587Study sitePhase 1Start 2026-05
  2. Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT06158841Study sitePhase 3Start 2024-05
  3. A Study to Learn About the Study Medicine (Maplirpacept) in People With Advanced Non-Hodgkin Lymphoma or Multiple Myeloma in ChinaCompletedNCT05896774Study sitePhase 1Start 2023-06
  4. A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)CompletedNCT04939142Study sitePhase 3Start 2021-07
  5. TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT03860038Study sitePhase 2Start 2019-01
  6. TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT03952091Study sitePhase 3Start 2019-03

Run the PubMed searchClinicalTrials.gov

Blood disorders

Thrombotic thrombocytopenic purpura

血栓性血小板减少性紫癜

Led 1 of the 64 English-language PubMed papers on thrombotic thrombocytopenic purpura with an author in mainland China, 2021–2025: 1.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

5 hospitals in Hangzhou for thrombotic thrombocytopenic purpura59 hospitals in China for thrombotic thrombocytopenic purpura

No open trial on thrombotic thrombocytopenic purpura lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

IgG4-related disease

IgG4相关性疾病

Led 3 of the 246 English-language PubMed papers on IgG4-related disease with an author in mainland China, 2021–2025: 1.2%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 1120242025: 002025

2 hospitals in Hangzhou for IgG4-related disease46 hospitals in China for IgG4-related disease

No open trial on IgG4-related disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesDiagnosis & look-alikesTreatment & relapseLung & chest

Run the PubMed searchClinicalTrials.gov

Other diseases

Myasthenia gravis

重症肌无力

Led no English-language PubMed papers on myasthenia gravis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution

6 hospitals in Hangzhou for myasthenia gravis93 hospitals in China for myasthenia gravis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
    Phase
    Phase 3
    Started
    2021-07
    Registry
    NCT04951622

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan, Shanghai, Tianjin, Xi'an

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status3
  1. A Study of Nipocalimab Administered to Adults With Generalized Myasthenia GravisRecruitingNCT04951622Study sitePhase 3Start 2021-07
  2. Study of Telitacicept in Generalized Myasthenia GravisCompletedNCT05737160Study sitePhase 3Start 2023-03
  3. A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia GravisTerminatedNCT04963270Study sitePhase 3Start 2021-10

Run the PubMed searchClinicalTrials.gov

Other diseases

Takayasu arteritis

大动脉炎

Led 1 of the 187 English-language PubMed papers on Takayasu arteritis with an author in mainland China, 2021–2025: 0.5%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

3 hospitals in Hangzhou for Takayasu arteritis108 hospitals in China for Takayasu arteritis

No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRheumatology & immunology
Papers it led1
  1. Phlebitis in Takayasu arteritis: A case-based literature review.2024International journal of rheumatic diseases

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led no English-language PubMed papers on idiopathic pulmonary fibrosis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution

9 hospitals in Hangzhou for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
    Phase
    Phase 3
    Started
    2026-09
    Registry
    NCT07687459

    Age 40 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Hohhot, Jinan, Kunming, Nanchang, Nanjing, Nanning, Nanyang, Ningbo, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wenzhou, Wuhan, Xi'an, Xiamen, Xuzhou, Yichang, Yuncheng, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Lymphangioleiomyomatosis

肺淋巴管平滑肌瘤病

Led 1 of the 45 English-language PubMed papers on lymphangioleiomyomatosis with an author in mainland China, 2021–2025: 2.2%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

1 hospital in Hangzhou for lymphangioleiomyomatosis28 hospitals in China for lymphangioleiomyomatosis

No open trial on lymphangioleiomyomatosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led no English-language PubMed papers on amyotrophic lateral sclerosis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

11 hospitals in Hangzhou for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Pompe disease

庞贝病

Led no English-language PubMed papers on Pompe disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Hangzhou for Pompe disease30 hospitals in China for Pompe disease

No open trial on Pompe disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology
Chinese-language papers (not in the count)1
  1. [Diagnosis and treatment of late onset Pompe disease: a case report].2024Zhonghua nei ke za zhi

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led 1 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

7 hospitals in Hangzhou for Behçet disease149 hospitals in China for Behçet disease

No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 3 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.4%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 112025

15 hospitals in Hangzhou for IgA nephropathy346 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology

Run the PubMed searchClinicalTrials.gov

Other diseases

Niemann–Pick disease type C

尼曼-匹克病 C 型

Led no English-language PubMed papers on Niemann–Pick disease type C in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

3 hospitals in Hangzhou for Niemann–Pick disease type C15 hospitals in China for Niemann–Pick disease type C

No open trial on Niemann–Pick disease type C lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led 1 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 0.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

11 hospitals in Hangzhou for primary biliary cholangitis173 hospitals in China for primary biliary cholangitis

No open trial on primary biliary cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary sclerosing cholangitis

原发性硬化性胆管炎

Led no English-language PubMed papers on primary sclerosing cholangitis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

7 hospitals in Hangzhou for primary sclerosing cholangitis90 hospitals in China for primary sclerosing cholangitis

No open trial on primary sclerosing cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Immunoglobulin G4-related sclerosing cholangitis mimicking cholangiocarcinoma: a case report and literature review.2020The Journal of international medical research

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

浙江大学医学院附属邵逸夫医院

Sir Run Run Shaw Hospital

杭州

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR Wikidata
Sir Run-Run Shaw Hospital; Affiliated Sir Runrun Shaw Hospital; Sir RunRun Shaw Hospital; Sir Run Run Shaw hospital; s Hospital Affiliated with Sir Run Run Shaw Hospital; Sir Run Run Shaw Hospital of Zhejiang University; Sir Run Run Shaw Hospital Xiasha Branch; Sir Run Run Shaw Hospital Xiasha Campus

Suggest a correctionDownload the data